Revolutionary insulin delivery technology to enhance care in type 1 diabetes

Biotech News: A spin-off company founded by three University of Sydney and Sydney Local Health District academics, has received $2.2 million in backing from an Australian biotech incubator to help bring their drug delivery technology to the clinic.

Endo Axiom’s technology aims to enable needle-free insulin delivery for children with Type 1 diabetes. The technology uses nanoparticles to safely deliver insulin into the bloodstream.

“We hope insulin is just the first of the usually injectable, life-saving medications we can deliver this way. Our work to date shows the nanoparticles we use are safe and excreted very quickly from the body. We are already testing other medications and our major goal is using the delivery system to not just treat, but to prevent disease development,” Professor Victoria Cogger, Director of the ANZAC Research Institute, said.

Results of the oral insulin program are currently undergoing peer review and the program is expected to enter clinical trials in 2024.

Deputy Vice-Chancellor (Research) Professor Emma Johnston said this work exemplifies the University of Sydney’s longstanding excellence in health and medical research and commitment to leveraging research to improve lives.

“I’m thrilled to see this research progressing to commercialisation. The potential to vastly improve the daily lives of those with Type 1 diabetes, particularly children, is an exciting development, and underscores the importance of what we as universities, and individual scientists, do for the communities we serve.”

Biotech incubator, Proto Axiom, will provide Endo Axiom with both financial investment and commercialisation expertise.

Anthony Liveris, Proto Axiom’s Chief Executive, said “We are privileged to have the opportunity to work with Endo Axiom. The team has produced world-leading research. As well as financially investing in the company, Proto will give the team access to industry knowledge and commercialisation expertise from both Australia and overseas.”

This is the first in a series of investments that Proto Axiom expects to announce in coming months.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.